Lit Matters + White Coat to Board Room

Lit Matters: PE Guideline Update

Acute pulmonary embolism is no longer framed as simply massive, submassive, or low risk. The 2026 AHA/ACC guideline replaces that scheme with a category-based PE severity model, links treatment to shock physiology and RV strain, and makes outpatient DOAC-based care the default for selected low-risk patients. New PE Severity Framework Category-based risk language: The old massive and submassive labels are gone, replaced by Categories A through E to better separate incidental PE, intermediate-risk disease, and overt hemodynamic failure. Intermediate-risk gray zone: Category C captures the normotensive patient with symptomatic PE, then separates C1, C2, and C3 by RV strain and biomarker burden rather than a single submassive bucket. Respiratory compromise modifier: An R-plus modifier flags hypoxia or tachypnea as a meaningful layer of severity even when blood pressure is preserved, a distinction worth hearing in the chapter. Shock without hypotension: Category D explicitly includes transient hypotension and normotensive shock with end-organ hypoperfusion, recognizing that preserved BP does not exclude impending collapse. Arrest-level PE severity: Category E separates overt shock from cardiac arrest, clarifying when PE has progressed from unstable physiology to a true crashing presentation. Management Changes in Acute PE Outpatient low-risk treatment: Categories A and B can often leave the hospital on anticoagulation if follow-up and medication access are in place, rather than defaulting to automatic admission. Limited role for procedures: For C1 PE, intervention has no recommended role, while catheter-based therapy or thrombectomy in C2 and C3 remains only a cautious may-consider option. Equivalent reperfusion options: In Category E1, systemic thrombolysis and catheter-based therapy now sit on similar footing instead of one clearly outranking the other. We get into the bedside implications in the episode. Immediate lytics in arrest: For Category E2 PE with crashing physiology or cardiac arrest, the headline move is push systemic thrombolytics without waiting for a longer deliberation. Anticoagulation simplification: LMWH is favored over unfractionated heparin, and apixaban or rivaroxaban are first-line outpatient agents, marking a shift away from routine heparin drips and warfarin. PERT and follow-up structure: Pulmonary Embolism Response Teams get strong guideline support, paired with an early check-in around one week and formal reassessment at three months.

White Coat to Board Room Part 1

Emergency physicians can extend their impact beyond the bedside by pairing frontline practice with business strategy, innovation, and global health. Maintaining clinical work keeps product decisions grounded in real patient needs, clinician behavior under uncertainty, and the financial realities that shape adoption. Emergency Medicine Beyond the Bedside Three-leg career framework: A durable nontraditional career can rest on medicine, business, and global health at the same time rather than forcing a single-lane choice. Clinical credibility in innovation: Ongoing emergency practice keeps innovation honest by exposing real workflow friction, patient needs, and how clinicians actually make decisions with incomplete data. Systems-scale impact mindset: The big opportunity is often system design rather than one-patient-at-a-time care, especially in resource-constrained settings where scalability matters most. Emergency physician skill transfer: Emergency medicine translates unusually well to strategy roles because rapid decisions, uncertainty tolerance, and systems thinking are core to both worlds, and we get into that crossover in the episode. Dual-career tradeoffs: Working clinical shifts while building business ventures is possible but gets harder over time as travel, family, and leadership demands compete for the same bandwidth. Building Innovation Inside Large Organizations Reverse innovation model: Products built for low-resource settings can move upstream into wealthy markets when simplicity, portability, and independence from infrastructure become advantages. Internal startup realities: Launching a new venture inside a corporation often starts with no team, no budget, and no template, making internal advocacy as important as the idea itself. Financial sustainability framing: Innovation gains traction faster when framed as a sustainable business rather than philanthropy, especially in organizations built around margin expectations. Volume versus margin tension: Lower-cost, higher-volume healthcare models can clash with traditional device economics, a practical tension that matters more than most clinicians realize. We walk through that conflict in the episode. Organizational influence mapping: Driving change in healthcare systems depends on identifying champions, understanding who influences whom, and tailoring the message to each stakeholder group. Business literacy for clinicians: Clinicians who understand incentives, organizational structure, and where the money flows are better positioned to move good ideas into real adoption.